Epigral Limited has announced a board meeting scheduled for January 30, 2026, to consider and approve the unaudited financial results for the third quarter (October-December) and nine months ended December 31, 2025. The board will also review the Limited Review Report of the Statutory Auditors.
Board Meeting for Financial Results
Epigral Limited’s board of directors will convene on January 30, 2026, to review and approve the company’s unaudited financial performance.
Financial Performance on the Agenda
The primary agenda includes the review and approval of the Un-audited Financial Results (Standalone & Consolidated) for the Third Quarter (October-December) and Nine Months period ending on December 31, 2025. The board will also consider the Limited Review Report prepared by the Statutory Auditors in relation to these financial results.
Source: BSE
